SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-027932
Filing Date
2024-03-07
Accepted
2024-03-07 16:05:52
Documents
14
Period of Report
2024-03-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pstx-20240305.htm   iXBRL 8-K 41524
2 EX-99.1 pstx-ex99_1.htm EX-99.1 148986
3 GRAPHIC img265366334_0.jpg GRAPHIC 25951
  Complete submission text file 0000950170-24-027932.txt   354795

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pstx-20240305.xsd EX-101.SCH 24823
15 EXTRACTED XBRL INSTANCE DOCUMENT pstx-20240305_htm.xml XML 4723
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Filer) CIK: 0001661460 (see all company filings)

IRS No.: 472846548 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39376 | Film No.: 24730056
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)